Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment for MM.
Difference in Daratumumab from Isatuximab
Robert Rifkin, MD, McKesson Biosimilars, Associate Chair, Rocky Mountain Cancer Centers showcases the difference from daratumumab and isatuximab and whether the drug is showing promise as a treatment for MM.